Microba Deal Gives Genetic Signatures a Larger Diagnostics Platform

Microba Shareholders Gain Majority Ownership

Microba Life Sciences shareholders are set to become the dominant owners of a larger ASX-listed diagnostics company under agreed commercial terms with Genetic Signatures Limited (ASX:GSS). Genetic Signatures would acquire all Microba shares and options through a scheme of arrangement, issuing approximately 469 million new GSS shares and leaving Microba shareholders with about 67% of the enlarged group.

The exchange ratio is 0.654 new GSS shares for every Microba share, with equivalent options issued to Microba option holders. Existing GSS shareholders would retain approximately 33% ownership, while the combined company would continue trading under the GSS code. No cash consideration or new acquisition financing is contemplated.

Two Diagnostics Platforms, One Commercial Group

The proposed merger brings together Genetic Signatures’ rapid molecular testing and pathogen detection technology with Microba’s metagenomic and microbiome testing capabilities. The companies say the combination would broaden their offering across gastrointestinal and infectious disease diagnostics rather than simply consolidate overlapping products.

The enlarged group would combine GSS’s hospital, reference laboratory and international distribution relationships with Microba’s clinician network, UK operations and pathology partnerships involving Sonic Healthcare and SYNLAB. Products from the two businesses are distributed across more than 30 countries, although the announcement does not provide a pro forma forecast for how the combined commercial platform would perform.

A$30 Million Cash Base and Estimated Savings

On a simple aggregation of reported figures, the proposed group would bring together approximately A$29.6 million of FY2026 revenue and A$30 million of cash and term deposits as at 30 June 2026. Genetic Signatures contributed A$14.8 million of revenue and A$22.1 million of cash and term deposits, while Microba reported the same revenue and A$7.9 million in cash and term deposits.

Preliminary analysis has identified A$2.5 million to A$3.0 million in potential annualised gross cost synergies, mainly through combining duplicated listed-company, corporate and administrative functions. Those figures are estimates, not committed savings: both businesses say they require further validation, integration planning and successful execution. The announcement also flags possible additional savings across procurement, distribution, manufacturing, laboratory operations and shared technical functions.

Equal Board Representation Before the Approval Process

The proposed board would comprise six directors, split evenly between three nominees from Genetic Signatures and three from Microba. Senior management arrangements and the final board composition remain subject to the definitive transaction documentation, so the governance outline is not yet the finished architecture of the combined company.

The immediate hurdle is GSS shareholder approval at a forthcoming extraordinary general meeting. Even if that vote passes, the parties must still execute a definitive Scheme Implementation Deed, obtain any required ASX and regulatory approvals, secure Microba shareholder and option holder approval, and receive Court approval. The combined financial figures are illustrative aggregations rather than pro forma financial information, and the proposed merger may not proceed if those conditions are not satisfied.